{
    "clinical_study": {
        "@rank": "164746", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
            }, 
            {
                "arm_group_label": "Pravastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg."
            }, 
            {
                "arm_group_label": "Rosuvastatin", 
                "arm_group_type": "Experimental", 
                "description": "The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg."
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the effects of rosuvastatin (maybe the highest diabetogenic) and pravastatin (seems\n      to be protective) on the glucose homeostasis and other biomarkers in subjects with impaired\n      fasting glucose."
        }, 
        "brief_title": "The Statins on Glucose Homeostasis in Subjects With Impaired Fasting Glucose", 
        "completion_date": {
            "#text": "December 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Prediabetic State"
            ]
        }, 
        "detailed_description": {
            "textblock": "Statin therapy effectively reduces cardiovascular events. However, trial data1 and\n      meta-analyses suggest that statins also confer increased risk of development of diabetes. In\n      order to elucidate whether statins increase risk of diabetes, investigators conducted this\n      study to evaluate the effects of rosuvastatin (maybe the highest diabetogenic) and\n      pravastatin (seems to be protective) on the glucose homeostasis and other biomarkers in\n      subjects with impaired fasting glucose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 35-70 years old\n\n          2. Fasting blood glucose 100-125 mg/dL\n\n        Exclusion Criteria:\n\n          1. A1C >7.0%\n\n          2. 2hr glucose during OGTT >200 mg/dL\n\n          3. Total cholesterol >280 mg/dL\n\n          4. Previous diabetic history, coronary artery disease\n\n          5. Allergy to rosuvastatin or parvastatin\n\n          6. Baseline ALT more than 3 times UNL\n\n          7. Serum Cr > 2.0 mg/dL\n\n          8. Pregnancy, breast feeding or plan to be pregnant woman."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01816997", 
            "org_study_id": "VGHIRB 2011-10-005IA"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pravastatin", 
                "description": "The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.\nIFG subjects with total cholesterol less than 200 mg/dL will be served as controls.", 
                "intervention_name": "Pravastatin", 
                "intervention_type": "Drug", 
                "other_name": "Pravastatin (Mevalotin)"
            }, 
            {
                "arm_group_label": "Rosuvastatin", 
                "description": "The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.\nIFG subjects with total cholesterol less than 200 mg/dL will be served as controls.", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Crestor"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "placebo", 
                "intervention_name": "Control", 
                "intervention_type": "Drug", 
                "other_name": "placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pravastatin", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Statins", 
            "Glucose homeostasis", 
            "Diabetes", 
            "Impaired fasting glucose"
        ], 
        "lastchanged_date": "November 15, 2013", 
        "location": {
            "contact": {
                "last_name": "Harn-Shen Chen, MD, PhD", 
                "phone": "886-2-28757515"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "11217"
                }, 
                "name": "Taipei Veterans General Hospital"
            }, 
            "investigator": {
                "last_name": "Harn-Shen Chen, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Influence of Statins on Glucose Homeostasis and the Biomarkers of Diabetes in Subjects With Impaired Fasting Glucose", 
        "overall_contact": {
            "email": "chenhs@vghtpe.gov.tw", 
            "last_name": "Harn-Shen Chen, MD, PhD", 
            "phone": "886-2-28757515"
        }, 
        "overall_official": {
            "affiliation": "Taipei Veterans General Hospital, Taiwan", 
            "last_name": "Harn-Shen Chen, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compare the glucose homeostasis and some biomarkers of diabetes among control, parvastatin and rosuvastatin groups.\nGlucose and insulin response during OGTT. Some markers of insulin resistance and insulin secretion calculated from OGTT.", 
            "measure": "Glucose homeostasis", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01816997"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Taipei Veterans General Hospital, Taiwan", 
            "investigator_full_name": "vghtpe user", 
            "investigator_title": "Taipei Veterans General Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Such as GLP-1, GIP, IGF-1, HbA1c, FPG etc.", 
                "measure": "Some biomarkers of diabetes", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "We will repeat FPG and A1C every 6 months and OGTT every 1-2 years for up to 10 years to investigate the change of these parameters.", 
                "measure": "Progression of glucose homeostasis", 
                "safety_issue": "No", 
                "time_frame": "5 to 10 years."
            }, 
            {
                "description": "Retinopathy: The change of steps on the ETDRS Severity Scales. Nephropathy: UACR and eGFR change. All-cause mortality", 
                "measure": "Chronic complications of diabetes", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "description": "We will repeat FPG and A1C every 6 months and OGTT every 1-2 years for up to 10 years to investigate the incidence of diabetes.", 
                "measure": "Incidence of diabetes", 
                "safety_issue": "No", 
                "time_frame": "5 to 10 years."
            }, 
            {
                "description": "Diabetic retinopathy: Development of advanced diabetic retinopathy. Advanced diabetic retinopathy was defined as development of proliferative diabetic retinopathy, retinopathy treated with laser photocoagulation or vitrectomy.\nNephropathy: Development of macroalbuminuria (UACR >30 mg/mmol creatinine), a severe decline in eGFR (<30 mL/[min\u20221.73 m2]).\nCardiovacular events: angina, myocardial infarction, heart failure, acute coronary syndrome and cerebrovascular accident.", 
                "measure": "Chronic complications of diabetes", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }
        ], 
        "source": "Taipei Veterans General Hospital, Taiwan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Taipei Veterans General Hospital, Taiwan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}